Analyst Joseph Pantginis from H.C. Wainwright maintained a Buy rating on Lexicon Pharmaceuticals and keeping the price target at $4.00.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Joseph Pantginis has given his Buy rating due to a combination of factors surrounding Lexicon Pharmaceuticals’ promising developments. The company has presented compelling Phase 2b data for pilavapadin in diabetic peripheral neuropathic pain (DPNP), highlighting the efficacy and safety of the 10 mg dose. This dosage demonstrated significant reductions in average daily pain scores (ADPS) and maintained a favorable safety profile, making it the optimal choice for advancing into Phase 3 trials.
Additionally, Lexicon’s strategic plans include an anticipated end-of-Phase 2 meeting with the FDA by the end of the year, which could pave the way for further clinical progress. The company is also actively seeking partnerships to bolster its development efforts. These factors combined suggest a strong potential for Lexicon’s future growth, justifying Pantginis’s Buy rating.
Pantginis covers the Healthcare sector, focusing on stocks such as Lexicon Pharmaceuticals, Capricor Therapeutics, and Travere Therapeutics. According to TipRanks, Pantginis has an average return of 1.7% and a 46.00% success rate on recommended stocks.